<DOC>
	<DOCNO>NCT01440959</DOCNO>
	<brief_summary>With discovery KIT mutation advent KIT tyrosine kinase inhibitor imatinib ( GlivecTM , Novartis ) , substantial improvement overall survival patient advance and/or metastatic gastrointestinal tumor ( GIST ) . Recently , sunitinib ( SuteneTM , Pfizer ) show activity second-line therapy GIST patient failure imatinib . However , virtually patient eventually progress become intolerable first-line imatinib second-line sunitinib . Dovitinib ( TKI258 , Novartis ) multi-kinase inhibitor . TKI258 potent inhibitor VEGFR 1 , 2 , 3 , FGFR1 , 2 3 , PDGFRβ , Kit , RET , TrkA , CSF 1R , FLT3 inhibitory concentration 50 % ( IC50s ) less 40nM . Stem cell factor ( SCF ) also term KIT ligand , steel factor show modulate tumor angiogenesis . In cultured human endothelial cell Kit express cancer cell , TKI258 inhibit VEGF- SCF-stimulated mitogenesis . .</brief_summary>
	<brief_title>Dovitinib Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors ( GIST )</brief_title>
	<detailed_description>It well know KIT PDGFR inhibit TKI258 crucial role development proliferation GIST , general FGFR important role angiogenesis tumor proliferation many cancer . We assume TKI258 also effective patient GIST . The objective study evaluate safety activity TKI258 give salvage treatment GIST failure standard imatinib sunitinib .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion Age 20 year old Histologically confirm metastatic and/or advance GIST CD117 ( + ) , DOG1 ( + ) , mutation KIT PDGFRα gene Failed ( progress and/or intolerable ) prior treatment GIST , include least imatinib sunitinib . ECOG performance status 0~2 Resolution toxic effect prior treatment grade 0 1 NCICTCAE version 3.0 At least one measurable lesion define RECIST version 1.0 . Adequate bone marrow , hepatic , renal , organ function Neutrophil &gt; 1,500/mm3 Platelet &gt; 75,000/mm3 Hemoglobin &gt; 8.0 g/dL Total bilirubin &lt; 1.5 x upper limit normal ( ULN ) AST/ALT &lt; 2.5 x ULN ( &lt; 5 x ULM case liver metastasis ) Creatinine &lt; 1.5 x ULN Amylase , lipase &lt; ULN Electrolytes within normal limit . Urine dipstick reading : Negative proteinuria , documentation +1 result protein dipstick reading , total urinary protein ≤ 500 mg measure creatinine clearance ≥ 50 mL/min/1.73m2 24hour urine collection Life expectancy &gt; 12 week Women reproductive potential must negative serum urine pregnancy test Washout period previous TKIs chemotherapy 4 time half life . Provision sign write informed consent Exclusion criterion Women childbearing potential pregnant breast feeding adult reproductive potential employ effective method birth control . Clinically significant cardiac disease ( New York Heart Association , Class III IV ) impair cardiac function clinically significant cardiac disease , Uncontrolled infection . Diabetes mellitus ( insulin dependent independent disease , require chronic medication ) sign clinically significant peripheral vascular disease . Previous pericarditis ; clinically significant pleural effusion previous month current ascites require two interventions/month . Known preexist clinically significant disorder hypothalamicpituitary axis , adrenal thyroid gland . Prior acute chronic pancreatitis etiology . Acute chronic liver disease chronic liver impairment . Malabsorption syndrome uncontrolled gastrointestinal toxicity toxicity great NCI CTCAE grade 2 . Other severe , acute , chronic medical psychiatric condition laboratory abnormality . Treatment medication potential risk prolong QT interval induce Torsades de Points treatment discontinue switched different medication prior start study drug . Use ketoconazole , erythromycin , carbamazepine , phenobarbital , rifampin , phenytoin quinidine 2 week prior baseline . Major surgery ≤ 28 day prior start study drug recover side effect therapy . Known diagnosis HIV infection . History another primary malignancy currently clinically significant currently require active intervention . Patients brain metastasis assess radiologic image Alcohol substance abuse disorder . inhibitor FGFR except sunitinib</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>This single-center</keyword>
	<keyword>prospective</keyword>
	<keyword>single-arm</keyword>
	<keyword>open-label phase II study</keyword>
</DOC>